Kolumne, ORE

Original-Research: Nabaltec AG - von NuWays AG Einstufung von NuWays AG zu Nabaltec AG Unternehmen: Nabaltec AG ISIN: DE000A0KPPR7 Anlass der Studie: Update Empfehlung: Kaufen seit: 26.04.2024 Kursziel: EUR 25.00 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: Analyst: Christian Sandherr Final FY23 as expected, solid start into FY24 2023 figures inline with prelims.

26.04.2024 - 09:01:33

Original-Research: Nabaltec AG (von NuWays AG): Kaufen


Original-Research: Nabaltec AG - von NuWays AG

Einstufung von NuWays AG zu Nabaltec AG

Unternehmen: Nabaltec AG
ISIN: DE000A0KPPR7

Anlass der Studie: Update
Empfehlung: Kaufen
seit: 26.04.2024
Kursziel: EUR 25.00
Kursziel auf Sicht von: 12 Monaten
Letzte Ratingänderung: 
Analyst: Christian Sandherr

Final FY23 as expected, solid start into FY24
 
2023 figures inline with prelims. To recap: FY23 sales decreased by 8.5%
yoy to EUR 200m, largely driven by the highly cyclical Specialty Alumina
segment, which reported sales of EUR 57.8m (-18.5% yoy). On the contrary,
Functional Fillers' sales decreased by only 3.9% to EUR 142.3m, as revenues
from boehmite and gap fillers grew by 6.1% yoy to EUR 22.4m, whereas boehmite
alone showed a 9% yoy sales decline. Positively, the FY EBIT margin stood
at 9.2% (-4.2pp yoy), EUR 18.3m absolute EBIT. Despite the muted operational
performance and a 14% increase of working capital, the company generated EUR
2m of FCF.
 
Nabaltec also released solid Q1 prelims, which render the FY24 guidance
sensible. Q1 sales decreased 5.3% yoy to EUR 54m, largely due to a tough
comparable base (Q1 FY23 with 4% growth vs a 12% decline during the
remainder of FY23). Compared to the average of the past three quarters, Q1
sales were up 14%. In fact, the EBIT margin slightly increased by 0.2pp yoy
to 9.3% (absolute EBIT of EUR 5m).
 
With this, the lower end of the FY24 EBIT margin guidance looks well in
reach, if not conservative as it implies a margin of only 6.2% for the
remainder of the year. This compares to our 8.2% margin estimate for the
rest of FY24e (eNuW: 3.9% yoy sales growth). As a reminder, management
expects to grow FY24 sales slightly with an EBIT margin of 7-9%. Growth is
expected to be carried by a slight increase of boehmite volumes (+1kt yoy),
further growing gap filler demand and improving utilization rates at its US
plants, while the remainder of F.F. and S.A. should remain rather flat yoy.
 
Boehmite retains plenty of potential. During the past two years, the
boehmite sales contribution decreased from EUR 24.2m in FY21 to EUR 17.3m last
year. The main reason behind this was a strong oversupply in China
(lacklustre EV demand growth), the core market for EV battery production
and a slower than initially expected ramp up of production capacities in
Europe and the US. Yet, with demand for ceramic coating solutions expected
to 4x until 2028, boehmite should return to growth; eNuW: from EUR 17m in
FY23 to EUR 25m by FY25e (conservatively below market growth).
 
In sum, Nabaltec is a cyclical company that has passed the demand trough
with a solid balance sheet, several structural growth drivers for core
products and upside from boehmite. Valuation seem to lag behind with shares
trading on 9/7x EV/EBIT FY24/25e. We confirm our BUY rating with an
unchanged EUR 25 PT based on FCFY 24e and keep Nabaltec in our NuWays Alpha
List.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/29535.pdf
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.

Kontakt für Rückfragen
NuWays AG  - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

-------------------übermittelt durch die EQS Group AG.-------------------


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

@ dpa.de

Weitere Meldungen

Original-Research: Nynomic AG (von Montega AG): Kaufen Original-Research: Nynomic AG - von Montega AG Einstufung von Montega AG zu Nynomic AG Unternehmen: Nynomic AG ISIN: DE000A0MSN11 Anlass der Studie: Update Empfehlung: Kaufen seit: 10.05.2024 Kursziel: 47,00 EUR (zuvor: 48,00 EUR) Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst: Miguel Lago Mascato Q1: Solider Jahresauftakt - Steigerung der ausgezeichneten H2/23-Performance & M&A-Newsflow erwartet Nynomic hat Mittwoch Q1-Zahlen veröffentlicht, die eine spürbare Steigerung ggü. (Boerse, 10.05.2024 - 16:16) weiterlesen...

Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH)... Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to MPH Health Care AG Company Name: MPH Health Care AG ISIN: DE000A289V03 Reason for the research: Vorläufige Ergebnisse 2023 Recommendation: Kaufen from: 10.05.2024 Target price: EUR81 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. (Boerse, 10.05.2024 - 12:41) weiterlesen...

Original-Research: Knaus Tabbert AG (von First Berlin Equity Research GmbH): ... Original-Research: Knaus Tabbert AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Knaus Tabbert AG Company Name: Knaus Tabbert AG ISIN: DE000A2YN504 Reason for the research: Dreimonatsbericht Recommendation: Kaufen from: 10.05.2024 Target price: EUR86 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu Knaus Tabbert AG (ISIN: DE000A2YN504) veröffentlicht. (Boerse, 10.05.2024 - 11:46) weiterlesen...

Original-Research: ZEAL Network SE (von NuWays AG): Kaufen Original-Research: ZEAL Network SE - from NuWays AG Classification of NuWays AG to ZEAL Network SE Company Name: ZEAL Network SE ISIN: DE000ZEAL241 Reason for the research: Recommendation: Kaufen from: 10.05.2024 Target price: EUR 53.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Henry Wendisch Staggering Q1 kicks off new growth phase; chg est. (Boerse, 10.05.2024 - 09:07) weiterlesen...

Original-Research: Nynomic AG (von NuWays AG): Kaufen Original-Research: Nynomic AG - from NuWays AG Classification of NuWays AG to Nynomic AG Company Name: Nynomic AG ISIN: DE000A0MSN11 Reason for the research: Update Recommendation: Kaufen from: 10.05.2024 Target price: EUR 52.00 Target price on sight of: 12 Monaten Last rating change: Analyst: Christian Sandherr Solid start into FY24 despite challenging end markets Topic: Nynomic published a solid start into the year with order intake returning to growth for the first time since Q3 2022. (Boerse, 10.05.2024 - 09:06) weiterlesen...

Original-Research: R. STAHL AG (von NuWays AG): Kaufen. STAHL AG - from NuWays AG Classification of NuWays AG to R. Original-Research: R. (Boerse, 10.05.2024 - 09:02) weiterlesen...